Drug Profile
Research programme: stem cell targeting therapeutics - Celprogen
Alternative Names: CEP 1205; CEP 1206; CEP 1207; CEP 1430; CEP 1507; CEP 3007; CEP 3009; CEP 3061; CEP 3095; CEP 4002; CEP 4021; CEP 5003; STEM 5007; STEMC 7007; STEMC5007Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Celprogen
- Class Small molecules
- Mechanism of Action Glucagon receptor agonists; Glucose transporter type 1 stimulants; Hedgehog cell-signalling pathway inhibitors; Insulin growth factor agonists; Somatostatin modulators; Stem cell modulators; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Brain cancer; Breast cancer; Colorectal cancer; Diabetes mellitus; Liver cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Stem cell mobilisation
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (IM)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Intraperitoneal)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (IV)